Business Context and Reporting Period
Company: Aastrom Biosciences, Inc. (Note: Input metadata referenced Vericel Corp, but the filing text identifies Aastrom Biosciences, Inc.)
Reporting Period: Quarter and nine months ended March 31, 2007.
Business Stage: Clinical development stage company focused on regenerative medicine using autologous cell products (Tissue Repair Cell or TRC Technology). The company has never been profitable and relies on equity financing and grants.
Key Financial Metrics
| Metric | Three Months Ended Mar 31, 2007 | Nine Months Ended Mar 31, 2007 | Balance Sheet (Mar 31, 2007) |
|---|---|---|---|
| Total Revenues | $258,000 | $520,000 | - |
| Net Loss | $(4,483,000) | $(12,765,000) | - |
| Net Loss Per Share (Basic/Diluted) | $(0.04) | $(0.11) | - |
| Cash & Cash Equivalents | - | - | $27,608,000 |
| Short-term Investments | - | - | $4,999,000 |
| Total Liquid Assets | - | - | $32,607,000 |
| Accumulated Deficit | - | - | $(154,915,000) |
| Current Liabilities | - | - | $2,293,000 |
Note: All figures in thousands except per share data.
Material Changes vs. Prior Period
- Revenue: Total revenue increased slightly for the quarter ($258k vs $238k) but decreased for the nine-month period ($520k vs $535k). Product sales declined significantly ($44k vs $85k for the quarter), while grant revenue increased ($214k vs $153k for the quarter).
- Expenses: Total costs and expenses increased to $5.18 million for the quarter (from $5.04 million) and $14.77 million for the nine months (from $13.47 million).
- R&D: Increased to $3.10 million (quarter) and $7.96 million (nine months) due to expanded clinical trials and regulatory submissions.
- SG&A: Decreased for the quarter to $2.07 million (from $2.44 million) due to lower salaries and recruitment costs, but increased for the nine months to $6.79 million (from $6.71 million) primarily due to a $257,000 non-cash stock-based compensation charge related to the former CEO's termination.
- Liquidity: Cash and short-term investments decreased by approximately $10.4 million from June 30, 2006, to March 31, 2007, driven by operating cash usage of $10.9 million.
Guidance, Outlook, and Risks
- Outlook: Management expects available cash and investments to fund operations beyond the end of fiscal year 2008 (June 30, 2008). Monthly cash utilization is estimated at approximately $1.5 million for the remainder of fiscal 2007.
- Clinical Progress:
- Bone Regeneration: FDA approved a Phase III trial for osteonecrosis of the femoral head (May 2007). Interim results for long bone fractures showed 90% healing in patients completing 12-month follow-up.
- Vascular Regeneration: Initiated a Phase IIb trial for critical limb ischemia in April 2007.
- Cardiac: Received Orphan Drug Designation for dilated cardiomyopathy; preparing trial protocols.
- Risks:
- Funding: Significant additional capital is required to complete clinical trials and commercialize products. Failure to raise funds could force delays or termination of programs.
- Regulatory: Success depends on FDA and EU approvals. Changes in regulatory classification or failure to demonstrate safety/efficacy could halt operations.
- Stock-Based Compensation: Potential future expense of $2.6 million to $3.2 million related to performance-based options if clinical milestones are deemed probable.
- Delisting: Risk of Nasdaq delisting if stock price remains below $1.00.
Investor Verification Checklist
- Verify the timeline and enrollment status of the Phase III osteonecrosis trial and Phase IIb critical limb ischemia trial.
- Confirm the company's ability to raise additional capital given the $1.5 million monthly burn rate and the need for funding beyond 2008.
- Monitor the status of performance-based stock options and the potential recognition of $2.6M–$3.2M in future compensation expenses.
- Review the impact of EU regulatory changes on the company's ability to conduct clinical trials in Europe.
- Assess the risk of Nasdaq delisting if the stock price fails to recover above the $1.00 threshold.